Takeaways: Elahere’s pCPA agreement advances AbbVie’s efforts to expand access to targeted treatment for FRα-positive, platinum-resistant ovarian cancer in Canada. Its demonstrated overall survi...
Browsing Tag: FRα-positive ovarian cancer
Takeaways: Elahere’s pCPA agreement advances AbbVie’s efforts to expand access to targeted treatment for FRα-positive, platinum-resistant ovarian cancer in Canada. Its demonstrated overall survi...